North America Epigenetics Diagnostic Market, By Product (Reagents, Kits, Instruments & Consumables, Bioinformatics Tools & Enzymes), Technology (DNA Methylation, Histone Methylation, Chromatin Structures, Histone Acetylation, Large Non-Coding RNA & MicroRNA Modification), Type of Therapy (Histone Deacetylase (HDAC) Inhibitors, DNA Methyltransferase (DNMT) Inhibitors & Others), Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Immunology, Inflammatory Diseases, Infectious Diseases & Others), End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) & Others), Distribution Channel (Direct Tender & Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2028.
Market Analysis and Insights: North America Epigenetics Diagnostic Market
North America epigenetics diagnostic market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.0% in the forecast period of 2021 to 2028 and is expected to reach USD 5,810.57 million by 2028 from USD 1,823.57 million in 2020. The high prevalence of chronic disorders and technological development is likely to be the major drivers which propel the demand of the market in the forecast period.
The epigenetics diagnostic is the study of genetics, cellular and physical trait variations and developmental biology which is caused by the external environmental. This in turn affects genes and cellular ability to read genes without being affected by changes in genotype. The epigenetics changes result into changes in phenotype of organism rather than genotype, the underlying DNA and RNA sequence remains unchanged. The epigenetic changes are essential for development as they are dynamic and change with respect to environment.
The genetic expressions of organism are effected by epigenetics, which is making it the most crucial field of molecular biology and developmental genetics. Organizations, such as the National Center Institute, the National Institute of Health, and the International Human Epigenome Consortium, are funding and supporting research and development activities pertaining to the field of epigenetics. Epigenetics is also used to treat a variety of chronic diseases such as cancer, metabolic diseases, and others.
The North America epigenetics diagnostic market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
North America Epigenetics Diagnostic Market Scope and Market Size
North America epigenetics diagnostic market is categorized into six notable segments which are based on product, technology, type of therapy, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the North America epigenetics diagnostic market is segmented into reagents, kits, instruments & consumables, bioinformatics tools, and enzymes. In 2021, reagents segment is expected to dominate the market as reagents are used in a variety of fields including research, diagnosis, bioscience, and education.
- On the basis of technology, the North America epigenetics diagnostic market is segmented into DNA methylation, histone methylation, chromatin structures, histone acetylation, large non-coding RNA, and microRNA modification. In 2021, DNA methylation segment is expected to dominate the market as the DNA methylation technology is being used in a variety of epigenetics diagnosis.
- On the basis of type of therapy, the North America epigenetics diagnostic market is segmented into histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) inhibitors, and others. In 2021, histone deacetylase (HDAC) inhibitors segment is expected to dominate the market as it plays a major role in biological processes and regulate gene expression.
- On the basis of application, the North America epigenetics diagnostic market is segmented into oncology, cardiovascular diseases, metabolic diseases, immunology, inflammatory diseases, and others. In 2021, oncology segment is expected to dominate the market due to the increasing use of epigenetics for cancer diagnosis.
- On the basis of end user, the North America epigenetics diagnostic market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others. In 2021, academic and research institutes segment is expected to dominate the market as various research institutes are performing research on the efficacy of epigenetics testing.
- On the basis of distribution channel, the North America epigenetics diagnostic market is segmented into direct tender and retail sales. In 2021, direct tender segment is expected to dominate the market due to escalation in marketing activities and improved customer services in North American region.
North America Epigenetics Diagnostic Market Country Level Analysis
North America epigenetics diagnostic market is analysed, and market size information is provided by country, product, technology, type of therapy, application, end user, and distribution channel.
The countries covered in the North America epigenetics diagnostic market report are U.S., Canada and Mexico.
The U.S. is expected to grow in North America epigenetics diagnostic market, due to the increasing demand for epigenetics diagnosis because of high prevalence of chronic diseases and increasing healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in the North America Epigenetics Diagnostic Market
North America epigenetics diagnostic market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the epigenetics diagnostic market. The data is available for the historic period 2010 to 2019.
Competitive Landscape and North America Epigenetics Diagnostic Market Share Analysis
North America epigenetics diagnostic market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to epigenetics diagnostic market.
Some of the major companies providing epigenetics diagnostic are Zymo Research Corporation, PerkinElmer Inc., Diagenode, F. Hoffman-La Roche Ltd, EPICYPHER, Promega Corporation, QIAGEN, Pacific Biosciences of California, Inc., Epigenomics AG, Mnemo, Reaction Biology, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Merck KGaA, Illumina, Inc., ACTIVEMOTIF, New England Biolabs, Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Enzo Life Sciences, Inc., Epizyme, Inc., GlaxoSmithKline plc., Eclipse BioInnovations, MDxHealth, Abcam plc, Salarius Pharmaceuticals, Inc., Datar Cancer Genetics and Bluestar Genomics Inc. among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players and new technological advancements for epigenetics diagnostic are bridging the gap for variety of treatments.
For instance,
- In May 2021, Abcam Plc., has announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. This expansion anticipated to escalate revenue growth of the company.
Collaboration, joint ventures, and other strategies by the market player is enhancing the company market in the epigenetics diagnostic market, which also provides the benefit for the organization to improve their offering for epigenetics diagnostic market.
SKU-